Dren Bio
Clinical trials sponsored by Dren Bio, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare blood cancers: first human trial launches Results expected Dec 2026 (estimated)
- New drug DR-01 tested for alopecia and vitiligo Results expected May 2027 (estimated)
- New antibody drug takes on Hard-to-Treat cancers Results expected Jul 2027 (estimated)
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug made available outside clinical trials for patients in need
Disease control Expanded accessThis program allows certain patients to receive dibotatug (DR-01) even if they cannot join a clinical trial. It is only for those with a doctor's request and who meet specific criteria. The goal is to provide access to a potential treatment when no other options are available.
Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…
Phase 1 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC